Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 541 to 550 of 901

TitleReference numberPublishedLast updated
Ocrelizumab for treating primary progressive multiple sclerosisTA585
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetesTA583
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancerTA584
Enzalutamide for hormone-relapsed non-metastatic prostate cancerTA580
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphomaTA577
Certolizumab pegol for treating moderate to severe plaque psoriasisTA574
Tildrakizumab for treating moderate to severe plaque psoriasisTA575
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)TA576
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetesTA572
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancerTA569

Results per page

  1. 10
  2. 25
  3. 50
  4. All